This is a "connection" page, showing publications co-authored by Barry Freedman and Todd Robinson.
Robinson TW, Freedman BI. The Impact of APOL1 on Chronic Kidney Disease and Hypertension. Adv Chronic Kidney Dis. 2019 03; 26(2):131-136.
Robinson TW, Freedman BI. Glycated albumin and blood sugar control in advanced chronic kidney disease. Nephrol Dial Transplant. 2018 07 01; 33(7):1087-1090.
Robinson TW, Freedman BI. APOL1 genotype, blood pressure, and survival in African Americans with nondiabetic nephropathy. Kidney Int. 2017 02; 91(2):276-278.
Robinson TW, Freedman BI. The Apolipoprotein L1 Gene and Cardiovascular Disease. Methodist Debakey Cardiovasc J. 2016 Oct-Dec; 12(4 Suppl):2-5.
Freedman BI, Robinson TW. Risk factors: familial aggregation of ESRD in Europeans-is it in the genes? Nat Rev Nephrol. 2014 12; 10(12):677-8.
Robinson TW, Freedman BI. Assessing glycemic control in diabetic patients with severe nephropathy. J Ren Nutr. 2013 May; 23(3):199-202.
Murea M, Brown WM, Divers J, Moossavi S, Robinson TW, Bagwell B, Burkart JM, Freedman BI. Vascular Access Placement Order and Outcomes in Hemodialysis Patients: A Longitudinal Study. Am J Nephrol. 2017; 46(4):268-275.
McLean NO, Robinson TW, Freedman BI. APOL1 Gene Kidney Risk Variants and Cardiovascular Disease: Getting to the Heart of the Matter. Am J Kidney Dis. 2017 Aug; 70(2):281-289.
Murea M, Geary RL, Edwards MS, Moossavi S, Davis RP, Goldman MP, Hurie J, Williams TK, Velazquez-Ramirez G, Robinson TW, Bagwell B, Tuttle AB, Callahan KE, Rocco MV, Houston DK, Pajewski NM, Divers J, Freedman BI, Williamson JD. A randomized pilot study comparing graft-first to fistula-first strategies in older patients with incident end-stage kidney disease: Clinical rationale and study design. Contemp Clin Trials Commun. 2019 Jun; 14:100357.